Search results for "Opioid use disorder"
Website launched for ACP partner program to help combat opioid crisis
ACP will offer expertise on using a quality improvement framework to reduce opioid use, support local and regional participation in the program, and serve in an advisory capacity for the broader program.
https://immattersacp.org/weekly/archives/2018/05/15/5.htm
15 May 2018
Mortality in year after overdose lower with methadone or buprenorphine treatment
Compared with no medications for opioid use disorder, methadone and buprenorphine were each associated with decreased all-cause and opioid-related mortality.
https://immattersacp.org/weekly/archives/2018/06/19/1.htm
19 Jun 2018
Multistate B. cepacia outbreak linked to foam cleanser
This column reviews details on recent recalls, warnings, and approvals.
https://immattersacp.org/archives/2018/07/multistate-b-cepacia-outbreak-linked-to-foam-cleanser.htm
1 Jul 2018
ACP offers new Practice Advisor module, webinars on use of opioids for chronic pain
The module, Opioid Risk Management, helps assess a practice's ability to successfully develop a treatment plan for chronic pain and track and monitor use of opioids if prescribed.
https://immattersacp.org/weekly/archives/2018/08/14/6.htm
14 Aug 2018
Registration open for ACP webinars on diabetes, opioids, and gender equity
Topics include “Update on Diabetes Mellitus,” “Managing Patients Not Benefiting From (or Being Harmed by) Opioids,” and “Putting Gender Equity Principles into Action.”
https://immattersacp.org/weekly/archives/2018/08/28/6.htm
28 Aug 2018
Breaking barriers to buprenorphine
Despite heightened awareness of the opioid crisis, treatment still eludes many patients who are struggling with addiction.
https://immattersacp.org/archives/2018/09/breaking-barriers-to-buprenorphine.htm
1 Sep 2018
Controlled substance agreements may reduce primary care visits, amid a decades-old, growing opioid crisis
Researchers retrospectively evaluated health care utilization changes among primary care patients receiving long-term opioid therapy for chronic noncancer pain who enrolled in a controlled substance agreement.
https://immattersacp.org/weekly/archives/2018/09/25/2.htm
25 Sep 2018
Daily medication appears more cost-effective than monthly injections for opioid use disorder
Over 24 weeks, extended-release naltrexone cost an average of $5,317 more than buprenorphine-naloxone, primarily because the former was more expensive and required a longer detoxification period.
https://immattersacp.org/weekly/archives/2018/12/18/1.htm
18 Dec 2018
More recalls, information on impurity found in ARBs
This column reviews details on recent recalls, warnings, and approvals.
https://immattersacp.org/archives/2019/01/more-recalls-information-on-impurity-found-in-arbs.htm
1 Jan 2019
Access to buprenorphine assessed by ‘secret shopper’ study
More than third of simulated patients who portrayed themselves as heroin users seeking treatment were unable to get an appointment with a buprenorphine prescriber, and access was even lower among those reporting Medicaid coverage.
https://immattersacp.org/weekly/archives/2019/06/04/1.htm
4 Jun 2019